Bispecific B-Cell Constructs for Selective ARID3a+ Autoimmune Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for autoimmune disorders like SLE involve broad side effects and lack the ability to predict disease flare-ups, with existing treatments targeting all B cells rather than specifically addressing ARID3a+ B cells producing pathogenic autoantibodies.

Innovation Solution

Development of therapeutic constructs targeting ARID3a+ B cells enriched for CD68 protein, which are specifically designed to target and disable AAB-producing B cells, using bispecific constructs that bind to both CD68 and CD20.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If pan-B cell depletion therapy is used, then disease activity is reduced, but broad undesirable side effects occur

Engineering Contradiction:

Improvedisease activity reductionVSAvoidbroad undesirable side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by targeting a specific subset of B cells (ARID3a+ B cells) rather than all B cells. The therapy uses CD68 and CD20 markers to identify and treat only the pathogenic B cell subset that produces autoantibodies, while preserving other functional B cell populations, thus reducing side effects while maintaining disease control

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the B cell population into different subsets based on ARID3a expression and CD68/CD20 marker profiles. By dividing B cells into ARID3a+ pathogenic subset and ARID3a- non-pathogenic subset, the therapy can selectively target only the harmful subset, improving efficacy while reducing harmful effects on other B cell functions

Inventive Principle:

Principle #1Segmentation

2Reliability

If current B cell targeting therapies are used, then autoimmune disease symptoms are treated, but the ability to predict disease flare-ups is lost

Engineering Contradiction:

Improvedisease treatment effectivenessVSAvoidpredictability of disease flare-ups

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent identifies ARID3a+ CD68+ B cells as predictive biomarkers for upcoming disease flare-ups. By detecting these cells in advance, the system enables preliminary action - treating patients before actual flare-ups occur, improving both prediction capability and treatment timing

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent establishes a feedback mechanism where ARID3a expression levels and CD68+ B cell counts serve as biomarkers to monitor disease status and predict future flare-ups. This feedback loop allows dynamic adjustment of therapy timing and intensity, improving both treatment effectiveness and predictive accuracy

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20260035476A1Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases

Publication Date: 2026.02.05 THE BOARD OF RGT UNIV OF OKLAHOMA

AI summary

Multispecific constructs, e.g., bispecific constructs, which comprise an anti-B cell binding arm that specifically binds to a B-cell-specific cell surface marker such as CD20, CD19, CD21, CD24, or CD38, and a second binding arm that specifically binds to CD68 protein, and optionally at least one additional binding arm, wherein the multispecific constructs bind specifically to naïve B cells which express transcription factor ARID3a. Methods of using the multispecific constructs to treat autoimmune disorders and/or diseases including but not limited to Systemic lupus erythematosus (SLE), and SLE flare-ups.